Wall Street Expects This Obesity Drug Stock to Skyrocket 35% Over the Next 12 Months
16/5 10:47
Bad news keeps coming for Novo Nordisk (NYSE: NVO). The Denmark-based drugmaker's share price has plunged roughly 55% below its high set last summer. Earlier this week, a study published in The New England Journal of Medicine revealed that patients taking Eli Lilly's Zepbound los...